
Late-stage cancer incidence may be a suitable alternative endpoint to cancer-specific mortality in lung and ovarian cancer screening trials, but not in breast, colorectal, or prostate cancer screening trials.


coremsg

In clinical trials of cancer screening, the incidence of late-stage cancer works as well as cancer-specific mortality as an endpoint for some cancers but not others.

Cancer Stage vs Mortality Endpoints in Screening Trials?

evaluating-the-relationship-between-cancer-stage-and-mortality-endpoints-in-screening-trials


Evaluating the Relationship Between Cancer Stage and Mortality Endpoints in Screening Trials
